Abstract
Objective
Low dosemethotrexate (MTX) is among the most commonly used drugs in rheumatology and rarely associated with neutropenia. It is generally observed as a result of improper use or in patients with risk factors for toxicity. This study aimed to demonstrate the clinical characteristics and short-term follow-up outcomes of patients who presented with neutropenia related to low-dose MTX therapy.
Methods
Patients (>18 years) who were referred to our clinic due to neutropenia (neutrophil <1500/mm³) associated with low-dose MTX use between October 2022 and April 2024 were retrospectively analyzed. We recorded patients’ demographics, MTX dosage, risks for toxicity, laboratory and clinical findings at the time of presentation, the treatments, duration of recovery from neutropenia and mortality rates.
Results
There were 9 patients followed for low-dose MTX-associated neutropenia; 6 were female, and the mean age was 71. Seven patients had pancytopenia. Improper high-dose (7.5-15 mg/d) usage was detected in 7 patients. Eight patients presented with mucositis, and 3 had febrile neutropenia. At presentation, mean leukocyte count was 1520/mm³, neutrophil count was 600/mm³, hemoglobin was 8.7 g/dL, and platelet count was 66000/mm³. All patients were started on intravenous leucovorin without granulocyte-colony stimulating factor treatment, and the mean time to improvement for neutropenia and leukopenia was 8 and 8.6 days, respectively. No cases of mortality were detected.
Conclusions
In most of our casesMTX-associated neutropenia resulted from improper use. With leucovorin monotherapy and infection control, neutropenia improved within 8 days.
Keywords: Methotrexate, neutropenia, pancytopenia, toxicity, leucovorin
References
Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;2013:CD000951.
Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61-6.
Sherbini AA, Gwinnutt JM, Hyrich KL, Verstappen SMM. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology (Oxford). 2022;61:3930-8.
Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272-6.
Mori S, Hidaka M, Kawakita T, et al. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PLoS One. 2016;11:e0154744.
Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13:1109-13.
Davey E, Isbister GK. Repeated daily dosing of weekly methotrexate therapy causing multiorgan toxicity: a case report. Toxicology Communications. 2023;7.
Vial T, Patat AM, Boels D, et al. Adverse consequences of low-dose methotrexate medication errors: data from French poison control and pharmacovigilance centers. Joint Bone Spine. 2019;86:351-5.
Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist. 2016;21:1471-82.
Chan BS, Dawson AH, Buckley NA. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? Clin Toxicol (Phila). 2017;55:88-96.
Cansu D, Teke H, Bodakçi E, Korkmaz C. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis? Clin Rheumatol. 2018;37:3419-25.
Dhillon, GS, Chauhan S, Jalal Y, Ghobrial Y, Ahmed B. Low-dose methotrexate toxicity presenting as pancytopenia. Cureus. 2022;14.
Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051-5.
Ajmani S, Preet Singh Y, Prasad S, et al. Methotrexate-induced pancytopenia: a case series of 46 patients. Int J Rheum Dis. 2017;20:846-51.
Aronoff GR. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philedelphia, PA: American College of Physicians; 2007, p.101.
